

49. A therapeutic composition useful in treating humans with *Moraxella catarrhalis* comprising at least one antibody directed against the polypeptide of claim 27 and a suitable pharmaceutical carrier.

REMARKS

Claims

Claims 1-26 have been canceled without prejudice or disclaimer of the subject matter therein. Applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims as originally filed, and any other claims supported by the specification.

New claims 27-49 have been introduced. No new matter is added.

Support

Support for the new claims is either apparent, or is as described in the text below. Support for the hybridization conditions may be found, for example, at page 14, line 20 through page 15, line 4. Support for the recitation of sequence relatedness such as in claim 40 may be found in the specification, for example, at pages 46-50.

205040-19587001

Closing Remarks

Allowance of the pending claims is respectfully requested.

Respectfully submitted,



Teresa O. Bittenbender
Registration No. 47,425
Attorney for Applicant

DECHERT
1717 Arch Street
4000 Bell Atlantic Tower
Philadelphia, PA 19103
Fax: (215) 994-2222
Attn: Teresa O. Bittenbender, Esq.
(215) 994-2213

10018551-040503
205040-19581001